Skip to main content
EVGN logo

Evogene Ltd.

EVGNNASDAQHealthcareBiotechnology

$0.39Today:- (-)1Y −68.01%

As of Oct 16, 2026 close

Market cap
$4.88M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.35$1.49
Volume (live)
-
Avg. volume (3M)
2.56M

Evogene (EVGN) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Evogene used $13.50M of cash in operating activities and spent $135.00K on capital expenditures. That left free cash flow of −$13.64M.

Evogene Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Evogene Ltd. (EVGN) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-14.16-14.82-25.95-29.84-30.45-26.21-19.12-20.81-20.84
Depreciation & Amortization1.141.382.612.582.232.732.772.022.15
Deferred Income Tax-0.010.01-0.030.090.010.010.020.030.01
Stock Based Compensation0.651.241.881.192.614.101.581.732.24
Change in Working Capital-1.25-3.31-0.40-0.771.66-1.43-1.00-0.16-0.20
Change in Accounts Receivable1.71-0.63-1.45-0.07-0.06-0.150.09-0.030.04
Change in Inventory-1.02-1.280.49-0.47-0.09-0.91-0.900.150.35
Change in Accounts Payable-0.26-0.630.74-0.420.92-0.03-0.12-0.11-0.09
Change in Other Working Capital-1.691.03-0.183.10-0.87-0.34-0.07-0.17-0.50
Other Operating Activities0.12-4.890.323.10-0.871.29-1.622.030.71
Net Cash from Operating Activities-13.50-19.70-21.58-23.68-24.72-19.51-17.36-15.16-15.93
Investing Activities
Capital Expenditures-0.14-0.63-0.79-1.17-0.85-0.68-0.90-0.37-0.59
Acquisitions0.080.000.000.000.000.0010.000.00-4.76
Purchases of Investments0.00-17.15-10.70-0.91-24.110.00-1.64-45.91-11.66
Sales/Maturities of Investments0.0027.346.9215.364.4010.1039.6863.6427.49
Other Investing Activities17.800.050.030.000.000.00-10.000.004.76
Net Cash from Investing Activities17.749.62-4.5413.27-20.579.4237.1417.3515.25
Financing Activities
Debt Repayment-0.53-0.89-0.84-0.80-0.58-0.64-0.600.000.00
Common Stock Issued4.285.628.450.0229.5818.6610.000.010.68
Other Financing Activities-10.36-0.0810.5410.120.792.36-0.100.300.81
Net Cash from Financing Activities-6.604.6618.159.3430.2820.379.000.300.81
Summary
Effect of Forex Changes on Cash0.02-0.05-0.25-2.281.101.210.16-0.110.07
Net Change in Cash-2.35-5.47-8.21-3.35-15.0111.4828.942.380.20
Cash at Beginning of Period15.3020.7728.9832.3346.2334.755.813.443.24
Cash at End of Period12.9615.3020.7728.9832.3346.2334.755.813.44
Free Cash Flow-13.64-20.33-22.36-24.85-25.56-20.20-18.26-15.54-16.52
Supplemental Disclosures
Interest Paid-0.070.120.170.320.24---
Income Taxes Paid-0.010.030.040.010.01---

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Evogene Cash Flow

What is Evogene's free cash flow?

Evogene had negative free cash flow of $13.64M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$13.50M minus $135.00K of capital expenditures.

How much does Evogene spend on capital expenditures?

Evogene spent $135.00K on capital expenditures in fiscal 2025, compared with $626.00K a year earlier.

Does Evogene pay dividends or buy back shares?

Evogene's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition